A Phase 3, Randomized, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Guselkumab in Participants With Fistulizing, Perianal Crohn's Disease
A Phase 3, Randomized, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Guselkumab in Participants With Fistulizing, Perianal Crohn's Disease
The purpose of this study to evaluate the clinical efficacy of guselkumab in fistulizing, perianal Crohn's disease and to assess the overall safety of guselkumab.
Inclusion Criteria:
Exclusion Criteria:
Orlando, Florida 32804, United States
North Terrace, 5000, Australia
Athens Attica, 115 28, Greece
Pécs, 7624, Hungary
Fukuoka-ken, 802-0077, Japan
Shinjuku-ku, 169-0073, Japan
Torun, 87 100, Poland